Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

invoX Makes 2nd Investment in pHion, a Belfast mRNA Vaccine Company

publication date: Jun 1, 2023

invoX Pharma, a UK subsidiary of Sino Biopharm (HK: 1177), completed a second investment tranche in pHion Therapeutics, a Belfast company developing mRNA vaccines for oncology and infectious diseases. pHion’s proprietary platform is designed to deliver anionic mRNA and saRNA molecules that evade detection and generate an antigen-specific CD8+ T-cell response. invoX positioned the investment as part of its strategy to be a fully integrated biopharma. One year ago, invoX paid $161 million to acquire another novel UK company, F-Star, a Cambridge, UK clinical stage company that develops bispecific drugs for immunotherapies. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital